A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and …
The COVID-19 pandemic has created significant concern for everyone. Recent data from
many worldwide reports suggest that most infections are caused by the Omicron variant and …
many worldwide reports suggest that most infections are caused by the Omicron variant and …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge
Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning?
Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show …
causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show …
Nirmatrelvir plus ritonavir: first approval
YN Lamb - Drugs, 2022 - Springer
Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) is a co-packaged combination of nirmatrelvir
and ritonavir tablets, intended for co-administration and developed for the treatment and …
and ritonavir tablets, intended for co-administration and developed for the treatment and …
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Y Zhou, KA Gammeltoft, LA Ryberg, LV Pham… - Science …, 2022 - science.org
The oral protease inhibitor nirmatrelvir is of key importance for prevention of severe
coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied …
coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied …
Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
A living WHO guideline on drugs for covid-19
Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …
earlier versions (available as data supplements). New recommendations will be published …